Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study
Free accessOtherFirst published online April, 2010
Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study
Background: Patients with diabetes mellitus and IGT have a high risk for cardiovascular events. It is tempting to speculate that these patients are often first seen by cardiologists.
Design: This cross-sectional study investigates the diabetes prevalence in cardiology care units and the correlated metabolic conditions as assessed by several circulating biomarkers.
Methods: Patients aged 55 or older with suspected or overt coronary heart disease were eligible for trial participation. Fasting blood samples were drawn from patients to determine HOMA score, glycaemic and lipid profile, and several risk biomarkers. An OGTT was performed in patients without known diabetes.
Results: We enrolled 530 patients (181 male, 349 female, mean age, 68±7 years) in this study from 22 German cardiology centres; 156 patients (29.4%) had known diabetes and OGTT revealed that 184 patients (34.7%) had no diabetes, 106 patients (20.0%) had IGT or IFG and 84 patients (15.9%) were newly diagnosed with diabetes. Increased cardiovascular risk as reflected by increased hsCRP, ICAM and MMP-9 values was observed in diabetes patients. A higher cardiovascular biomarkers risk profile was seen in the IGT/IFG cohort.
Conclusions:This study confirms the observation that one third of patients of a cardiologic care unit suffer from impaired glucose regulation. Furthermore, the cardiology patients with previously unknown glucose homeostasis abnormalities had a higher prevalence of macrovacular disease and an impaired biomarker risk profile. This study underlines the importance of joint treatment efforts by cardiologists in concert with diabetologists for treatment of this patient group at high risk for cardiovascular events.
Martin S., Schramm W., Schneider B., et al. (2007) Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes115: 495-501.
2.
Mainous AG III , Baker B. , Koopman RJ, et al. (2007) Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia50: 934-40.
3.
Bartnik M., Norhammar A., Rydén L. ( 2007) Hyperglycaemia and cardiovascular disease. J Intern Med262: 145-56.
4.
Norhammar A. , Lindbäck J., Rydén L., Wallentin L., Stenestrand U. (2007) Improved but still high short and long-term mortality after myocardial infarction in patients with diabetes mellitus. A time trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission . Heart;93: 1577-83.
5.
Bartnik M., Rydén L., Ferrari R., et al. (2004) Abnormal glucose regulation in patients with coronary artery disease across Europe. Diabetologia47(suppl. 1): A61.
6.
Lauruschkat AH, Anrich B., Albert AA, et al. (2005) Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. Circulation112: 2397-402.
7.
Rathmann W., Haastert B., Icks A., et al. (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000. Diabetologia46: 182-9.
8.
Rathmann W., Icks A., Haastert B., Giani G., Löwel H., Mielck A. ( 2002) Undiagnosed diabetes mellitus among patients with prior myocardial infarction. Z Kardiol91: 620-5.
9.
Aronson D., Rayfield EJ, Chesebro JH ( 1997) Mechanism determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med126: 296-306.
10.
Taubert G., Winkelmann BR, Schleiffer T., et al. (2003) Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J145: 285-91.
11.
Rydén L., Standl E., Bartnik M., et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J28: 88-136.
12.
Hauner H., Hanisch J., Bramlage P., et al. (2008) Prevalence of undiagnosed type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and cardiovascular Risk Project (GEMCAS). Exp Clin Endocrinol Diabetes;116: 18-25.
13.
Erdmann E. ( 2005) Diabetes and cardiovascular risk markers. Curr Med Res Opin21(Suppl 1): S21-8.
14.
Lenzen M., Rydén L., Ohrvik J., et al. (2006) Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J27: 2969-74.
15.
Liu J., Grundy SM, Wang W., et al. (2007) Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J153: 552-8.
16.
Pankow JS, Kwan DK, Duncan BB, et al. (2007) Cardio-metabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care30: 325-7.
17.
Rijkelijkhuizen JM, Nijpels G., Heine RJ, Bouter LM, Stehouwer CDA, Dekker JM (2007) High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care30: 332-6.
18.
Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR, Australian Diabetes Society, Australian Diabetes Educators Association (2007) Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association . Med J Aust186: 461-5.
19.
Pfützner A., Kunt T., Mondok A., et al. (2004) Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care27: 682-7.
20.
Leonhardt W. , Pfützner A., Müller I., et al. (2008) Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: a sub-analysis from the PIOSTAT study . Atherosclerosis201: 155-62.
21.
Forst T., Pfützner A., Lübben G., et al. (2007) Effect of simvastatin and/or piogliazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism56: 491-6.
22.
Hanefeld M. , Marx N., Pfützner A., et al. (2007) Antiinflammatory effect of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitive CRP: the PIOSTAT study. J Am Coll Cardiol49: 291-8.
23.
Thrainsdottir IS, Aspelund T., Hardarson T., et al. (2005) Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur J Cardiovasc Prev Rehabil12: 465-71.
24.
Wallander M. , Bartnik M., Efendic S., et al. (2005) Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia48: 2229-35.
25.
Tamita K., Katayama M., Takagi T., et al. (2007) Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction . Circ J71: 834-41.
